Domperidone‑Induced QT‑Interval Prolongation: Guideline Recommendations
1. Classification of QT‑Prolonging Risk
- The ACC/AHA/ESC cardiovascular guidelines list domperidone among anti‑emetics with “less frequent” QT‑prolonging potential, placing it in the same risk tier as cisapride, certain anti‑infectives, and antipsychotics. 1
2. Mechanism of Action
- Domperidone blocks the rapidly activating delayed‑rectifier potassium current (I_Kr), the primary electrophysiological pathway by which most drugs delay cardiac repolarisation and prolong the QT interval. 3
3. Critical QT‑Threshold Management
- When a patient’s corrected QT interval (QTc) reaches ≥ 500 ms, domperidone must be stopped immediately and continuous cardiac telemetry initiated because this threshold markedly raises the risk of torsades de pointes. 3
4. Patient‑Specific Risk Factors that Amplify QT Prolongation
| Risk factor | Context / Evidence |
|---|---|
| Female sex – the strongest demographic risk factor for drug‑induced QT prolongation. | Guideline recommendation based on pooled data. [3] |
| Electrolyte disturbances – hypokalaemia and hypomagnesaemia are the most common reversible contributors. | Guideline recommendation. [3] |
| Bradycardia or recent conversion from atrial fibrillation | Identified in European Heart Journal risk stratification. [2] |
| Congestive heart failure or left‑ventricular hypertrophy | Identified in European Heart Journal risk stratification. [1] |
| Baseline QT prolongation or congenital long‑QT syndrome | Guideline recommendation. [3] |
| Concomitant use of other QT‑prolonging drugs (e.g., macrolides, fluoroquinolones, antipsychotics, antidepressants) | Guideline recommendation. [3] |
| Drug interactions that inhibit domperidone metabolism (e.g., CYP3A4 inhibitors) | Guideline recommendation. [3] |
5. Monitoring and Management When Domperidone Is Used
- Baseline ECG with QTc measurement should be obtained before starting domperidone, especially if other QT‑prolonging agents are co‑prescribed. 5
- Electrolyte optimisation prior to therapy: ensure serum potassium > 4.5 mmol/L and magnesium > 2.0 mg/dL (or equivalent). 3
- Discontinuation criteria – stop domperidone immediately if QTc exceeds 500 ms or if QTc increases by > 60–70 ms from baseline. 3
6. Safer Antiemetic Alternatives When QTc ≥ 500 ms
- Aprepitant (NK₁‑receptor antagonist) – does not prolong QT and is the preferred substitute. 4
- Dexamethasone – no QT risk; explicitly recommended as an alternative. 4
- Olanzapine – negligible QT‑prolongation potential at anti‑emetic doses. 4
7. Drug‑Interaction Vigilance
- Clinicians should consult crediblemeds.org (or similar interaction databases) before adding any medication to a patient receiving domperidone, as interacting drugs can dramatically increase QT‑risk. 7
All statements are derived from guideline‑level evidence (ACC/AHA/ESC, European Heart Journal, Circulation, Journal of the American College of Cardiology). No patient‑identifiable data are included.